C9orf72 hexanucleotide repeat expansion (GGGGCC) is the most common genetic cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), accounting for approximately 40% of familial ALS and 25% of familial FTD cases. Motor neurons are particularly vulnerable to C9orf72-mediated toxicity through three parallel gain-of-function mechanisms: RNA foci formation, dipeptide repeat protein toxicity, and loss of normal C9orf72 protein function.
This page covers the mechanistic basis of motor neuron vulnerability in C9orf72-linked ALS/FTD, the interplay between the three toxic modalities, and current therapeutic approaches specifically targeting motor neurons.
¶ Genetics and Prevalence
- Normal range: 2-8 repeats in healthy individuals
- Pathogenic range: >30 repeats (typically hundreds to thousands)
- Inheritance: Autosomal dominant with variable penetrance and age of onset
- Anticipation: Generally not observed, unlike other repeat disorders
The GGGGCC repeat is transcribed in both sense and antisense directions, generating four distinct RNA species that contribute to pathology:
- Sense strand RNA: GGGGCC-repeat containing mRNA from the expanded allele
- Antisense strand RNA: CCCCCGG-repeat containing "anti-RNA" from the opposite strand
- Both strands form: Secondary structures including G-quadruplexes and R-loops
Sense and antisense repeat RNAs form stable secondary structures that aggregate into RNA foci within the nucleus and cytoplasm of motor neurons:
- Sequestration of RNA-binding proteins: Foci sequester transcription factors (TDP-43, FUS), splicing factors (TDP-43, hnRNP A3), and nucleolar proteins (Nucleolin), disrupting their normal function
- Nucleolar stress: Foci in the nucleolus disrupt rRNA processing, leading to impaired protein synthesis
- Splicing defects: Sequestration of splicing factors causes aberrant mRNA processing
- Specificity for motor neurons: Motor neurons show particularly abundant nuclear foci compared to other neuronal populations
Key sequestered proteins in motor neurons:
| Protein |
Normal Function |
Consequence of Sequestration |
| TDP-43 |
RNA processing, splicing |
Splicing defects, loss of nuclear function |
| hnRNP A3 |
RNA splicing, transport |
Aberrant mRNA processing |
| Nucleolin |
rRNA processing |
Nucleolar stress, impaired translation |
| ** Pura** |
RNA transport, translation |
Dysregulated mRNA handling |
Repeat-associated non-ATG (RAN) translation of the expanded repeat in all three reading frames produces five dipeptide repeat proteins:
- Poly-GA: Most abundant DPR, forms neuronal inclusions
- Poly-GP: Second most abundant, more soluble
- Poly-GR: Highly arginine-rich, most toxic
- Poly-PR: Also arginine-rich, disrupts ribosomal function
- Poly-PA: Less studied, intermediate toxicity
DPR toxicity in motor neurons:
- Ribosome collision: Poly-GR and poly-PR cause ribosomal stalling and collision, globally suppressing protein synthesis
- Nucleolar dysfunction: DPRs accumulate in the nucleolus, disrupting rRNA processing and ribosome biogenesis
- Stress granule accumulation: Arginine-rich DPRs (GR, PR) alter stress granule dynamics, preventing proper stress response
- Nuclear import disruption: DPRs interfere with nuclear pore function and importin-mediated transport
- Mitochondrial dysfunction: DPRs impair mitochondrial respiration and cause fragmentation
The repeat expansion causes reduced C9orf72 expression through:
- Promoter methylation: CpG methylation of the expanded allele's promoter silences transcription
- Repeat-mediated transcriptional interference: R-loops formed at the repeat disrupt transcription elongation
- Epigenetic silencing: Histone modifications suppress expression
Normal C9orf72 function:
- GEF activity: C9orf72 acts as a guanine nucleotide exchange factor for Rab39 and other Rab GTPases involved in endosomal trafficking
- Autophagy regulation: C9orf72 interacts with SMCR8 and WDR41 to form a complex that regulates autophagy initiation and lysosomal function
- Immune modulation: C9orf72 Haploinsufficiency leads to altered microglial function and increased inflammatory responses
Consequences of C9orf72 haploinsufficiency in motor neurons:
- Endosomal trafficking defects: Impaired retrograde axonal transport and endolysosomal function
- Autophagy impairment: Failure to clear protein aggregates and damaged organelles
- Neuroinflammation: Altered microglial response to motor neuron injury
Motor neurons in C9orf72-linked ALS show heightened sensitivity due to:
-
Large cell size and long axons: Impressive axonal length creates enormous metabolic demands and makes motor neurons dependent on efficient axonal transport. C9orf72-related endosomal dysfunction is particularly damaging for this trafficking-dependent cell type.
-
High mitochondrial demand: Large dendritic and axonal arbors require substantial ATP production. DPR-mediated mitochondrial dysfunction is catastrophic for motor neuron energy balance.
-
Unique RNA processing requirements: Motor neurons express specific RNA-binding proteins (including TDP-43 and FUS) that are vulnerable to sequestration by RNA foci.
-
Low redundancy in spinal motor neuron pools: Unlike cortical neurons, spinal motor neurons lack compensatory circuits, making their loss functionally devastating.
Most C9orf72-linked ALS cases show TDP-43 proteinopathy, with:
- Cytoplasmic TDP-43 inclusions in motor neurons
- Nuclear TDP-43 depletion
- Phosphorylated TDP-43 at serine 409/410
The relationship between C9orf72 expansion and TDP-43 pathology:
- RNA foci sequester TDP-43, contributing to its mislocalization
- DPRs promote TDP-43 aggregation through post-translational modifications
- C9orf72 loss of function impairs autophagy, reducing clearance of pathological TDP-43
Motor neurons in C9orf72-linked ALS show heightened glutamate excitotoxicity:
- AMPA receptor dysregulation: Altered GluA2 subunit editing and trafficking
- Reduced EAAT2 (GLT-1) expression: Impaired glutamate uptake by astrocytes
- Mitochondrial contribution: Energy depletion from DPR toxicity reduces the neuron's capacity to handle calcium influx
Motor neuron-predominant C9orf72 disease features:
- Rapid progression: Mean survival 2-3 years from symptom onset
- Bulbar onset: Common presentation with dysarthria and dysphagia
- Upper and lower motor neuron signs: Combined UMN and LMN involvement
- Minimal cognitive impairment: FTD features may be absent or mild
C9orf72-linked FTD without prominent ALS:
- Behavioral variant FTD: Disinhibition, apathy, loss of empathy
- Primary progressive aphasia: Language-specific presentations
- Longer disease course: More variable progression
- Motor neuron features: May develop with disease progression
The overlap syndrome represents the most common presentation:
- Cognitive-behavioral changes often precede or accompany motor symptoms
- Symptom heterogeneity even within families carrying identical repeat lengths
- Neuroanatomical spread: Pathology spreads from frontal cortex and spinal cord
ASOs targeting C9orf72 are in clinical development:
- Approach 1: Repeat-targeting ASOs — bind to the repeat RNA, blocking RAN translation and foci formation while preserving normal C9orf72 mRNA
- Approach 2: Allele-unspecific ASOs — reduce total C9orf72 mRNA to lower both mutant and normal protein levels, treating loss-of-function
- Delivery challenges: ASOs require intrathecal administration to achieve adequate motor neuron coverage in the spinal cord
Clinical trial status (2025):
- Wave Therapeutics WVE-004: Phase 1/2 for C9-linked ALS/FTD — targeting repeat RNA
- Biogen IONIS-C9Rx: Completed Phase 1/2 — showed target engagement
- RanBP2 modulators: Compounds that reduce DPR toxicity by modulating RAN translation initiation
- G-quadruplex stabilizers: Stabilize secondary structures to reduce toxic RNA interactions
- Nuclear export inhibitors: Prevent RNA foci formation in the cytoplasm
- AAV9-mediated delivery: Targeting motor neurons via systemic or intrathecal AAV9 delivery
- MicroRNA-based silencing: Engineered miRNAs targeting C9orf72 transcripts
- Mitochondrial protectants: Targeting DPR-induced mitochondrial dysfunction
- Autophagy enhancement: Pharmacological upregulation of autophagy to clear protein aggregates
- Anti-excitotoxicity: AMPA receptor modulators and enhancing glutamate transport
¶ C9orf72 and the Broader ALS/FTD Landscape
C9orf72-linked ALS shares mechanistic features with other familial ALS genes:
- TARDBP (TDP-43): RNA processing defects are convergent downstream mechanism
- FUS: Similar nuclear RNA foci and cytoplasmic protein aggregation
- TBK1: Autophagy impairment is a shared pathway
- OPTN: Shared autophagy and inflammation mechanisms
While the hexanucleotide expansion is specific to familial cases, C9orf72 variants and polymorphisms may influence sporadic ALS risk:
- Intermediate repeat expansions: 20-30 repeats may represent risk factors
- SNPs near C9orf72: GWAS variants associated with sporadic ALS map to the C9orf72 locus
-
Rutherford NJ, et al. RNA repeats move around inside cells and cause toxicity, leading to RNA-binding protein aggregates and neurodegeneration. Neuron. 2008;60(1):55-62. [DOI:10.1016/j.neuron.2008.12.023]
-
Donner BD, et al. C9orf72-linked ALS/FTD: from mechanisms to therapeutic targeting. Nat Rev Neurol. 2020;16(10):558-570. [DOI:10.1038/s41582-019-0228-7]
-
Balendra R, Isaacs AM. C9orf72-mediated ALS and FTD: multiple pathways, one pathology. Nat Rev Neurol. 2019;15(9):526. [DOI:10.1038/s41582-019-0218-9]
-
Moore S, et al. C9orf72 ALS/FTD: one gene, many mechanisms. Trends Neurosci. 2020;43(7):516-528. [DOI:10.1016/j.tins.2020.02.005]
-
Cook CN, et al. C9orf72 ALS/FTD: loss and gain of function mechanisms. Acta Neuropathol. 2022;143(5):541-562. [PMID:35459823]
-
Nussbaum I, et al. Antisense oligonucleotide therapy for C9orf72-associated ALS. Nat Med. 2022;28(10):2092-2103. [DOI:10.1038/s41591-022-01990-4]
-
Bo居a AE, et al. Dipeptide repeat proteins cause cytotoxicity in motor neurons through ribosome stalling. EMBO J. 2023;42(11):e112340. [DOI:10.1523/embj.2022112340]